S. Swerdlow, E. Campo, N. Harris, E. Jaffe, S. Pileri et al., WHO 498 Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2008.

A. Alizadeh, M. Eisen, R. Davis, C. Ma, I. Lossos et al., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, vol.303, issue.6769, pp.503-514, 2000.
DOI : 10.1038/35000501

G. Wright, B. Tan, A. Rosenwald, E. Hurt, A. Wiestner et al., A gene expression- 504 based method to diagnose clinically distinct subgroups of diffuse large B cell 505 lymphoma, Proceedings of the National Academy of Sciences of the United States of 506

J. Huang, W. Sanger, T. Greiner, L. Staudt, D. Weisenburger et al., The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile, Blood, vol.99, issue.7, pp.2285-90, 2002.
DOI : 10.1182/blood.V99.7.2285

M. Pfeifer, M. Grau, D. Lenze, S. Wenzel, A. Wolf et al., PTEN loss 511 defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B- 512 cell lymphoma, Proceedings of the National Academy of Sciences of the United States 513 of America, pp.12420-12425, 2013.

G. Lenz, G. Wright, N. Emre, H. Kohlhammer, S. Dave et al., Molecular 515 subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways, 516 Proceedings of the National Academy of Sciences of the United States of America, pp.13520-13525, 2008.

G. Lenz and L. Staudt, Aggressive lymphomas. The New England journal of medicine, pp.1417-1446, 2010.

K. Savage, S. Monti, J. Kutok, and G. Cattoretti, The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma, Blood, vol.102, issue.12, pp.3871-80, 2003.
DOI : 10.1182/blood-2003-06-1841

J. Reichel, A. Chadburn, P. Rubinstein, L. Giulino-roth, W. Tam et al., Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells, Blood, vol.125, issue.7, pp.1061-73, 2015.
DOI : 10.1182/blood-2014-11-610436

G. Salles, D. De-jong, W. Xie, A. Rosenwald, M. Chhanabhai et al., Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium, Blood, vol.117, issue.26, pp.7070-529, 2011.
DOI : 10.1182/blood-2011-04-345256

S. Mareschal, P. Ruminy, C. Bagacean, V. Marchand, M. Cornic et al., Accurate 531 Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B, p.532

D. Scott, A. Mottok, D. Ennishi, G. Wright, P. Farinha et al., 536 Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined 537 by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. 538 Journal of clinical oncology : official journal of the American Society of Clinical 539 Oncology, pp.2848-56, 2015.

J. Lohr, P. Stojanov, M. Lawrence, D. Auclair, B. Chapuy et al., Discovery 541 and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by 542 whole-exome sequencing, Proceedings of the National Academy of Sciences of the 543 United States of America, pp.3879-84, 2012.

R. Morin, K. Mungall, E. Pleasance, A. Mungall, R. Goya et al., Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing, Blood, vol.122, issue.7, pp.1256-65, 2013.
DOI : 10.1182/blood-2013-02-483727

C. Mullighan, Genome sequencing of lymphoid malignancies. Blood. American 548 Society of Hematology, pp.3899-907, 2013.

R. Morin, N. Johnson, T. Severson, A. Mungall, J. An et al., Somatic 550 mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of 551 germinal-center origin. Nature genetics, pp.181-186, 2010.

R. Morin, M. Mendez-lago, A. Mungall, R. Goya, K. Mungall et al., 553 Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma, Nature, vol.554476, pp.298-303, 2011.

V. Ngo, R. Young, R. Schmitz, S. Jhavar, X. W. Lim et al., Oncogenically 556 active MYD88 mutations in human lymphoma, Nature, vol.557470, pp.115-124, 2011.
DOI : 10.1038/nature09671

L. Pasqualucci, V. Trifonov, G. Fabbri, J. Ma, D. Rossi et al., Analysis of 559 the coding genome of diffuse large B-cell lymphoma. Nature genetics. Nature 560 Publishing Group, pp.830-837, 2011.

J. Zhang and V. Grubor, Genetic heterogeneity of diffuse large B-cell lymphoma, 562 Proceedings of the National Academy of Sciences, pp.1398-403, 2013.
DOI : 10.1073/pnas.1205299110

C. Steidl and R. Gascoyne, The molecular pathogenesis of primary mediastinal large B-cell lymphoma, Blood, vol.118, issue.10, pp.2659-69, 2011.
DOI : 10.1182/blood-2011-05-326538

O. Ritz, C. Guiter, F. Castellano, K. Dorsch, J. Melzner et al., Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma, Blood, vol.114, issue.6, pp.1236-1278, 2009.
DOI : 10.1182/blood-2009-03-209759

URL : https://hal.archives-ouvertes.fr/inserm-00411059

A. Khodabakhshi, R. Morin, and A. Fejes, Recurrent targets of aberrant somatic hypermutation in lymphoma, Oncotarget, vol.3, issue.11, pp.1308-1327, 2012.
DOI : 10.18632/oncotarget.653

E. Bohers, S. Mareschal, P. Bertrand, P. Viailly, S. Dubois et al., 571 Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next 572

Y. Yang, A. Shaffer, N. Emre, M. Ceribelli, M. Zhang et al., Exploiting 595 synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer cell, pp.723-760, 2012.

L. Brault, T. Menter, E. Obermann, S. Knapp, S. Thommen et al., PIM 598 kinases are progression markers and emerging therapeutic targets in diffuse large B-cell 599 lymphoma. British journal of cancer, pp.491-500, 2012.
DOI : 10.1038/bjc.2012.272

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405213

J. Schuetz, N. Johnson, R. Morin, D. Scott, K. Tan et al., BCL2 601 mutations in diffuse large B-cell lymphoma. Leukemia, pp.20121383-90

Z. Xu-monette, L. Wu, C. Visco, Y. Tai, A. Tzankov et al., Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study, Blood, vol.120, issue.19, pp.3986-97, 2012.
DOI : 10.1182/blood-2012-05-433334

R. Schmitz, R. Young, M. Ceribelli, S. Jhavar, X. W. Zhang et al., Burkitt 608 lymphoma pathogenesis and therapeutic targets from structural and functional 609 genomics, Nature. Nature Publishing Group, vol.490, pp.116-136, 2012.
DOI : 10.1038/nature11378

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3609867

S. Momose, S. Weißbach, J. Pischimarov, T. Nedeva, E. Bach et al., The 611 diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is 612 also a gray zone of the mutational spectrum, Leukemia, p.613, 2015.

R. Schmitz, M. Hansmann, V. Bohle, J. Martin-subero, S. Hartmann et al., TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and 615 primary mediastinal B cell lymphoma. The Journal of experimental medicine, pp.616981-616990, 2009.

M. Weniger, I. Melzner, C. Menz, S. Wegener, J. Bucur-a et al., Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation, Oncogene, vol.28, issue.18, pp.2679-84, 2006.
DOI : 10.1038/sj.onc.1209151

C. Steidl, S. Shah, B. Woolcock, L. Rui, M. Kawahara et al., MHC class II 624 transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers, Nature, vol.625471, pp.377-81, 2011.
DOI : 10.1038/nature09754

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902849

Y. Maréchal, X. Pesesse, Y. Jia, V. Pouillon, D. Pérez-morga et al., Inositol 1,3,4,5-tetrakisphosphate controls proapoptotic Bim gene expression and survival in B cells, Proceedings of the National Academy of Sciences, vol.104, issue.35, pp.13978-83, 2007.
DOI : 10.1073/pnas.0704312104

H. Tagawa, S. Karnan, Y. Kasugai, S. Tuzuki, R. Suzuki et al., MASL1, a candidate oncogene found in amplification at 8p23.1, is translocated in immunoblastic B-cell lymphoma cell line OCI-LY8, Oncogene, vol.23, issue.14, pp.2576-81, 2004.
DOI : 10.1038/sj.onc.1207352

S. Jeromin, S. Weissmann, C. Haferlach, F. Dicker, K. Bayer et al., SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients, Leukemia, vol.98, issue.1, pp.108-125, 2014.
DOI : 10.1038/leu.2013.263

R. Lapalombella, Q. Sun, K. Williams, L. Tangeman, S. Jha et al., Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia, Blood, vol.120, issue.23, pp.4621-4655, 2012.
DOI : 10.1182/blood-2012-05-429506

S. Mareschal, H. Lanic, P. Ruminy, C. Bastard, H. Tilly et al., The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age, Haematologica, vol.96, issue.12, pp.1888-90, 2011.
DOI : 10.3324/haematol.2011.050617

K. Dunleavy, S. Pittaluga, L. Maeda, R. Advani, C. Chen et al., Dose- 642 adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. The New 643 England journal of medicine, pp.1408-1424, 2013.
DOI : 10.1056/nejmoa1214561

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568999

C. Récher, B. Coiffier, C. Haioun, T. Molina, C. Fermé et al., Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial, The Lancet, vol.378, issue.9806, pp.1858-67, 2011.
DOI : 10.1016/S0140-6736(11)61040-4

D. Trinh, D. Scott, R. Morin, M. Mendez-lago, A. J. Jones et al., Analysis of FOXO1 mutations in diffuse large B-cell lymphoma, Blood, vol.121, issue.18, pp.3666-74, 2013.
DOI : 10.1182/blood-2013-01-479865

C. Fernández-rodríguez, B. Bellosillo, M. García-garcía, B. Sánchez-gonzález, E. Gimeno-651 et al., MYD88 (L265P) mutation is an independent prognostic factor for 652 outcome in patients with diffuse large B-cell lymphoma. Leukemia. Nature Publishing 653 Group, pp.2104-2110, 2014.

E. Bohers, P. Viailly, S. Dubois, P. Bertrand, C. Maingonnat et al., 655 Somatic mutations of cell-free circulating DNA detected by Next Generation 656 Sequencing reflect the genetic changes in both Germinal Center B-Cell like and 657

B. Activated, Cell like Diffuse Large B-Cell Lymphoma tumors at the time of diagnosis, Haematologica. Haematologica, vol.658, 2015.